scispace - formally typeset
B

Barbara Wirleitner

Researcher at University of Innsbruck

Publications -  115
Citations -  4824

Barbara Wirleitner is an academic researcher from University of Innsbruck. The author has contributed to research in topics: Neopterin & Homocysteine. The author has an hindex of 35, co-authored 109 publications receiving 4452 citations. Previous affiliations of Barbara Wirleitner include Innsbruck Medical University.

Papers
More filters
Journal ArticleDOI

Moderate hyperhomocysteinemia and immune activation.

TL;DR: Moderate hyperhomocysteinemia is associated with an increased risk of atherosclerosis, thrombosis and neurodegenerative diseases, and the question is addressed, whether effects attributed to homocysteine, are not rather the consequence of folate and vitamin B12-deficiency.
Journal ArticleDOI

Rapid measurement of total plasma homocysteine by HPLC

TL;DR: A new HPLC assay for rapid and sensitive measurement of total plasma homocysteine, more convenient and more rapid than methods described earlier, and well suited for analysis of thiols in blood specimens is developed.
Journal ArticleDOI

Aspirin down‐regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro

TL;DR: The parallel influence of aspirin on both biochemical pathways implies that there was no direct inhibitory effect of aspirinon IDO; rather, it inhibits production of IFN‐γ in mitogen‐treated PBMC.
Journal ArticleDOI

In vitro Effects of Beet Root Juice on Stimulated and Unstimulated Peripheral Blood Mononuclear Cells

TL;DR: Data show that beetroot extract is able to counteract pro-inflammatory cascades in peripheral blood mononuclear cells, and beneficial effect of beetroot extracts may relate to this anti-inflammatory capacity.
Journal ArticleDOI

Pregnancy and birth outcomes following fresh or vitrified embryo transfer according to blastocyst morphology and expansion stage, and culturing strategy for delayed development

TL;DR: It is suggested that vitrification of non-top quality blastocysts as well as delayed cavitating and blastulating Day 5 embryos should be considered in autologous IVF cycles.